Phase II Study of Active Immunotherapy With Mature, Human Telomerase Reverse Transcriptase Messenger RNA -Transfected, Autologous Dendritic Cells (DC) Administered In A Prime-Boost Format to Subjects With Metastatic Prostate Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dendritic cell vaccines
- Indications Prostate cancer
- Focus Adverse reactions
Most Recent Events
- 02 Dec 2011 Biomarkers information updated
- 10 Feb 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Jul 2010 New trial record